MPM BioImpact Research
Investment Thesis
MPM BioImpact is a Boston-based biotechnology investment platform built to "transform scientific breakthroughs into life-saving medicines." It is the successor investment platform to MPM Capital, carrying forward more than 30 years of biotech venture investing while adding a public-markets and impact-investing layer. The firm's stated goal is to back companies that materially transform outcomes for patients suffering from serious disease, spanning oncology, immunology and autoimmune disease, RNA and cell therapeutics, rare disease, and mental health/neuroscience. MPM BioImpact is a signatory to the Operating Principles for Impact Management (OPIM), with independent BlueMark verification of its impact-management practices, distinguishing it from a purely returns-driven biotech VC.
Stage Focus
MPM BioImpact invests "longitudinally across the spectrum of drug development, at every stage from seed round to follow-on," and explicitly spans both private venture rounds and public/crossover investing. It frequently incubates and founds companies from scratch (Aktis Oncology, K2 Therapeutics, ReNAgade Therapeutics, Firefly Bio), leads or co-leads early rounds, and continues to invest through Series B/C, PIPEs, and public offerings as companies mature and IPO.
Check Size
Exact check-size ranges are not publicly disclosed. Observed round participation ranges from a $50M seed financing for K2 Therapeutics (2026) up to leading a PIPE of up to $306.9M for DBV Technologies (2025) and co-leading a $103M Series A for Reunion Neuroscience alongside Novo Holdings (2024), indicating the firm writes checks across a wide range depending on stage and round size.
Lead Tendency
Both. MPM BioImpact founds and leads seed/Series A rounds for companies it incubates (K2 Therapeutics, Aktis Oncology, Firefly Bio), leads follow-on financings and PIPEs (DBV Technologies), and also participates as an existing investor in later rounds led by others (Crossbow Therapeutics Series B led by Taiho Ventures/Arkin Bio Capital; Aktis Oncology Series B led by RA Capital).
Recent Activity
MPM BioImpact has been highly active through 2025–2026:
- August 2026: Seeded and helped launch K2 Therapeutics ($50M seed, Singapore-based)
- July 2026: Portfolio company Firefly Bio acquired by Johnson & Johnson
- March 2026: Participated in Crossbow Therapeutics' $77M Series B
- February 2026: Portfolio company Orna Therapeutics acquired by Eli Lilly (up to $2.4B)
- January 2026: Portfolio company Aktis Oncology priced an upsized IPO (~$318M gross proceeds; NASDAQ: AKTS)
- March 2025: Led a PIPE of up to $306.9M in DBV Technologies
- January 2025: Promoted Rami Rahal to Partner and appointed Brian Shuster as Entrepreneur Partner
- May 2024: Co-led Reunion Neuroscience's $103M Series A with Novo Holdings
- September 2024: Aktis Oncology closed an oversubscribed $175M Series B
Fund status reads as actively deploying, with new company creation (K2 Therapeutics, 2026) alongside a steady cadence of follow-on and exit activity.
Portfolio Highlights
MPM BioImpact's active/recent portfolio includes Aktis Oncology (radiopharmaceuticals, NASDAQ: AKTS), Cullinan Therapeutics (formerly Cullinan Oncology), Dyne Therapeutics, Entrada Therapeutics, Umoja Biopharma, Frontier Medicines, NextPoint Therapeutics, Crossbow Therapeutics, K2 Therapeutics, DBV Technologies, Reunion Neuroscience, ElevateBio, AstronauTx, āshibio, Antiva Biosciences, Photys Therapeutics, ReCode Therapeutics, Tizona Therapeutics, Arialys, Protego, SeaWolf, and Fable. Notable exits include Orna Therapeutics (acquired by Eli Lilly for up to $2.4B, 2026) and Firefly Bio (acquired by Johnson & Johnson, 2026). The firm's historical track record spans 60 FDA-approved drugs and 120+ M&A/IPO events over 30+ years, including argenx (VYVGART) as a landmark early success.
Team
- Ansbert Gadicke, M.D. — Chairman, Managing Partner, co-founder
- Christiana (Chris) Bardon, M.D., M.B.A. — Managing Partner
- Detlev Biniszkiewicz, Ph.D. — Managing Director
- Todd Foley, M.B.A. — Managing Director
- Kristen Laguerre, M.B.A. — Executive Partner
- David Kolesky, Ph.D. — Principal
- David Moskowitz, Ph.D., M.S. — Principal
- Binsen Li, Ph.D. — Principal
- Rami Rahal, Ph.D. — Partner (promoted January 2025)
- Sam Goldman, Ph.D. — Senior Associate
- Wu Jie, M.S. — Head of APAC
- Pankaj Bhargava, M.D.; Briggs Morrison, M.D.; Frank Neumann, M.D., Ph.D.; Aparna Parikh, M.D.; Matthew Roden, Ph.D.; Andrew M. Scharenberg, M.D.; Brian Shuster, M.B.A.; Elizabeth Stoner, M.D. — Entrepreneur Partners providing operating and clinical-development expertise
- Christopher Wolf, M.B.A. — Chief Financial Officer
- Robert Risoleo, J.D. — General Counsel
- Carolyn Bertozzi, Ph.D. — Chairperson, Medical and Scientific Advisory Board (Nobel laureate)
Decision Process
MPM BioImpact operates as a multi-partner investment platform (two Managing Partners, several Managing Directors and Principals) supported by a large bench of physician/scientist Entrepreneur Partners who help source, found, and operationally support companies. This structure points to a partnership-style decision process rather than a solo-GP model, with Entrepreneur Partners playing a hands-on role in company creation and governance.
Founder Preferences
MPM BioImpact frequently founds and incubates companies itself, pairing scientific founders with an Entrepreneur Partner (often a former pharma R&D or clinical-development executive) who takes an operating role. The firm favors deep science with a clear translational/clinical path — radiopharmaceuticals, circular RNA, in vivo cell therapy, T-cell engagers — over platform-only or purely computational biotech plays.
Geographic Focus
Headquartered in Boston, MA, with US biotech as the core focus and an expanding Asia-Pacific presence (Head of APAC, Meiji Seika Pharma partnership on virology/new technologies, K2 Therapeutics based in Singapore). Portfolio companies are concentrated in the Boston/Cambridge and broader US biotech hubs.